Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9600392 | 0.84 | L3MBTL1 (0.38) | L3MBTL1POLB | |
| SCHEMBL12566554 | 0.82 | GAA (0.48) | GAAL3MBTL1POLBSMN1; SMN2ALOX15 | |
| SCHEMBL9600708 | 0.81 | ALDH1A1 (0.38) | GAASMN1; SMN2ALOX15 | |
| SCHEMBL9600683 | 0.80 | PLA2G2A (0.40) | GAASMN1; SMN2ALOX15 | |
| SCHEMBL9600835 | 0.78 | PLA2G2A (0.41) | GAASMN1; SMN2ALOX15 | |
| SCHEMBL7139392 | 0.71 | GAA (0.42) | GAAL3MBTL1POLBSMN1; SMN2ALOX15 | |
| SCHEMBL12208453 | 0.71 | GAA (0.42) | GAAL3MBTL1POLBSMN1; SMN2ALOX15 | |
| SCHEMBL7148826 | 0.71 | GAA (0.46) | GAAL3MBTL1POLBSMN1; SMN2ALOX15 | |
| SCHEMBL7145277 | 0.71 | GAA (0.42) | GAAL3MBTL1POLBSMN1; SMN2ALOX15 | |
| SCHEMBL12709502 | 0.71 | GAA (0.42) | GAAL3MBTL1POLBSMN1; SMN2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167001-A1 | Pyridazinone-derivatives as pde4 inhibitors | ALTANA PHARMA AG (DE) | 2006-07-27 | — | — | US | claimed |
| US-6953853-B2 | Phospholipase inhbitors; antiinflammatory agents; respiratory system disorders | ALTANA PHARMA AG (DE) | 2005-10-11 | — | — | US | claimed |
| EP-1556369-A1 | PYRIDAZINONE-DERIVATIVES AS PDE4 INHIBITORS | ALTANA Pharma AG (DE) | 2005-07-27 | — | — | EP | claimed |
| US-20040067946-A1 | Phthalatyinone-piperidino-derivatives as pde4 inhibitors | TAKEDA GMBH (DE) | 2004-04-08 | — | — | US | claimed |
| WO-2004018451-A1 | PYRIDAZINONE-DERIVATIVES AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2004-03-04 | — | — | WO | claimed |
| EP-1362044-A1 | PHTHALAZINONE-PIPERIDINO-DERIVATIVES AS PDE4 INHIBITORS | ALTANA Pharma AG (DE) | 2003-11-19 | — | — | EP | claimed |
| US-6566355-B1 | Useful in combination with beta -lactam antibiotics in the control of beta -lactamase forming pathogens | HOFFMANN-LA ROCHE INC. | 2003-05-20 | — | — | US | claimed |
| WO-2002064584-A1 | PHTHALAYINONE-PIPERIDINO-DERIVATIVES AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2002-08-22 | — | — | WO | claimed |
| US-5712268-A | Compositions of tricyclic β-lactams and uses thereof | HOFFMANN-LA ROCHE INC. (US) | 1998-01-27 | — | — | US | claimed |
| US-5698577-A | ANTIBIOTICS | HOFFMANN-LA ROCHE INC. (US) | 1997-12-16 | — | — | US | claimed |
| US-5510343-A | BETA-LACTAMASE INHIBITOR | HOFFMANN-LA ROCHE INC. (US) | 1996-04-23 | — | — | US | claimed |
| EP-0294789-B1 | Process for preparing 6-/D(-)-Alpha-(4-ethyl-2,3-dioxo-1-piperazine-carboxamido)-phenylacetamido/pennicillanic acid | KRKA TOVARNA ZDRAVIL (YU) | 1994-10-12 | — | — | EP | claimed |
| US-5300497-A | Broad spectrum antibiotics and bactericides; stable to beta-lactamase; effective against antibiotic-resistant bacteria | TOYAMA CHEMICAL CO., LTD. (JP) | 1994-04-05 | — | — | US | claimed |
| US-5185330-A | Penicillins/ad/ | TOYAMA CHEMICAL CO., LTD. (JP) | 1993-02-09 | — | — | US | claimed |
| US-4822790-A | ANTIMICROBIOCIDES OR BETA-LACTAMASE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-04-18 | — | — | US | claimed |
| EP-0092830-A2 | Cephalosporin derivatives, process for their preparation, pharmaceutical compositions containing them and their application | CIBA-GEIGY AG (CH) | 1983-11-02 | — | — | EP | claimed |
| US-4283333-A | α-[4-Oxoazetidin-1-yl]-acetic acid compounds useful as intermediates in preparing 1-oxadethiacephalosporins | SHIONOGI & CO., LTD. (JP) | 1981-08-11 | — | — | US | claimed |
| US-4066641-A | METHOD FOR CYCLIZATION TO GIVE CEPHEM RING | HAMASHIMA YOSHIO | 1978-01-03 | — | — | US | claimed |
| JP-57118571-A | — | — | None | — | — | JP | disclosed |
| US-4066641-A | METHOD FOR CYCLIZATION TO GIVE CEPHEM RING | HAMASHIMA YOSHIO | 1978-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067946-A1 | Phthalatyinone-piperidino-derivatives as pde4 inhibitors | PDE4A, PDE4B, PDE5A | GAA 770/4885L3MBTL1 4529/4885POLB 1848/4885 |
| US-20060167001-A1 | Pyridazinone-derivatives as pde4 inhibitors | PDE4A, PDE3A, PDE4B | GAA 607/4885L3MBTL1 4523/4885POLB 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.